Polypid Ltd (PYPD) - News Archive

Transforming Cancer Treatment: PolyPid and ImmunoGenesis Join Forces to Revolutionize Immunotherapy with PLEX Technology In a groundbreaking move set to push the boundaries of modern cancer treatment, PolyPid Ltd. and I...

PolyPid s Momentum in Antimicrobial Innovations: Unveiling the SHIELD II Phase 3 Trial The recent announcement by PolyPid marks a significant stride in the arena of antimicrobial therapies with the Data and Safety Monit...

PolyPid Ltd. Navigates Compliance Hurdle While Advancing Pioneering TrialsPETACH TIKVA, Israel, Nov. 29, 2024 PolyPid Ltd. (Nasdaq: PYPD), a distinguished late-stage biopharmaceutical company committed to enhancing surg...

Surgical site infections (SSIs) represent a significant challenge in the landscape of post-operative care, particularly following abdominal colorectal surgeries. These infections not only contribute to increased morbidi...

PolyPid Secures Funding to Extend Cash Runway and Achieves High Leverage RatioPETACH TIKVA, Israel - In a recent press release, PolyPid Ltd. (Nasdaq: PYPD) has announced that it has successfully secured funding that wil...

PolyPid Poised to Revolutionize Post-Surgical Care: A Closer Look at the Upcoming KOL Event and D-PLEX Phase 3 Trial Progress By Author s Name for CSIMarket.com In the fast-paced arena of biopharmaceutical innovation, f...

Surgical site infections (SSIs) are a serious concern, particularly in abdominal colorectal procedures, as they can lead to increased morbidity, prolonged hospital stays, and significant healthcare costs. PolyPid, a lea...

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price RulePETACH TIKVA, Israel, Oct. 11, 2023 - PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical...